The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study (PLUMM)

Efficacy & Safety of Pharmacokinetically-Driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis- A Double-Blind Placebo Controlled Clinical Trial

The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA >60-70 mg*h/L. The study goal is to determine the safety and efficacy of MMFPK compared to MMFBSA for the treatment of proliferative LN in subjects 8 to <18 years.

Study Overview

• Status: Recruiting
• Conditions: Lupus Nephritis
• Intervention / Treatment: Drug: Mycophenolate Mofetil; Drug: Mycophenolate Mofetil

Detailed Description

Subjects will be randomized 1:1 to receive blinded treatment with MMFPK or MMFBSA for up to 53 weeks. The primary endpoint, clinical remission of LN, is measured at the end of Part 1 at week 26. Subjects in the MMFBSA arm who have only partial renal response (PRR) at the end of Part 1 will newly receive MMFPK upon entering Part 2 of the study (week 26 - 53). Subjects with complete renal responses (CRR) at the end of Part 1 will continue the same dosing regimen of MMF (MMFBSA or MMFPK) in Part 2 as was given in Part 1 of the study. Subjects in the MMFPK arm with PRR at the end of Part 1 will enter Part 2 and continue in the MMFPK arm.

Subjects who are LN non-responders by the end of Part 1 at week 26 will be considered treatment failures and discontinued from the study intervention. All subjects who are discontinued from the study intervention for reasons of efficacy or safety will receive LN treatment and monitoring as per the treating physician's decision. However, these subjects will be asked to participate in study visits at weeks 26 and 53/End of Study.

• Study Type: Interventional
• Enrollment (Estimated): 105
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Angela Sr CRC; Phone Number: 513-803-2118; Email: plumm@cchmc.org

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60614
      • Recruiting
      • Ann & Robert H. Lurie Children's Hospital of Chicago
      • Contact: Maria Amoruso; Phone Number: 312-227-6276; Email: MAmoruso@luriechildrens.org
      • Principal Investigator: Pooja Patel, DO
  • New Jersey
    • Hackensack, New Jersey, United States, 07601
      • Recruiting
      • Hackensack University Medical Center
      • Contact: Amanda Nowakowski; Phone Number: 551-996-3114; Email: amanda.nowakowski@hmhn.org
      • Principal Investigator: Anna Carmela Gironella, MD
  • New York
    • New York, New York, United States, 10021
      • Recruiting
      • Hospital for Special Surgery
      • Principal Investigator: Karen Onel, MD
      • Contact: Julia Klauss; Phone Number: 212-774-2703; Email: klaussj@HSS.EDU
    • New York, New York, United States, 10467
      • Recruiting
      • Children's Hospital at Montefiore
      • Principal Investigator: Dawn Wahezi, MD
      • Contact: Lisbel Guzman; Email: lisbel.guzman@einsteinmed.edu
      • Principal Investigator: Beatrice Goilav, MD
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • Recruiting
      • University of North Carolina at Chapel Hill
      • Principal Investigator: Eveline Wu, MD
      • Contact: Carolina Pastrana-Medina; Email: carol825@med.unc.edu
      • Principal Investigator: Laura Cannon, MD
  • Ohio
    • Cincinnati, Ohio, United States, 45223
      • Recruiting
      • Cincinnati Children's Hospital Medical Center
      • Contact: Angela; Phone Number: 513-338-4396; Email: plumm@cchmc.org
      • Principal Investigator: Hermine I Brunner, MD
  • Texas
    • Houston, Texas, United States, 77030
      • Recruiting
      • Baylor College of Medicine Pediatric Immunology Allergy Rheumatology
      • Contact: Monica Guevara; Phone Number: 832-824-1206; Email: Monica.Guevara@bcm.edu
      • Principal Investigator: Marietta DeGuzman, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 years to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion

1. Male or female aged 8 to < 18 years;
2. Must meet Classification Criteria for SLE as per the criteria of the American College of Rheumatology (ACR)/ European League Against Rheumatism 1-3 (Appendix 0);

3. Newly diagnosed with proliferative LN as per the International Society of Nephrology/Renal Pathology Society4 based on kidney biopsy done within 60 days prior to enrollment into the study;

   Subjects may have been previously diagnosed with other Classes of LN. For study inclusion, the kidney biopsy must be newly interpreted as one of the following classes: Class 3, Class 3/5, Class 4, or Class 4/5.

4. SLEDAI renal domain score > 0;

5. Treatment of LN with twice daily MMF as per the decision of the treating physician.

   The subject will have taken MMF as prescribed by their treating physician for a minimum of 4 days (or 8 doses).

6. Subject tolerates MMF as per the treating physician's opinion;
7. Able to swallow MMF tablets and capsules;
8. If subject is treated with belimumab, must be IV or SQ;
9. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
10. Evidence of a personally signed and dated Informed Consent document and Assent document (as appropriate) indicating that the subject and a legally acceptable representative/ parent(s)/legal guardian has been informed of all pertinent aspects of the study.
11. Parent or legal guardian must have a smart phone available and able to support the PLUMM smart phone application.
12. Must be able to complete study questionnaires in English or Spanish.

Exclusion Criteria:

1. Perceived or stated inability to adhere to the study protocol;
2. Hypersensitivity to MMF or any component of the drug product;
3. Presence of features (from SLE or other chronic disease) that a-priori suggest that the subject benefits from other therapies than that suggested or allowable by the study protocol; These disease features include but are not limited to severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
4. History of other kidney disease besides LN or prior to the diagnosis of SLE;
5. Need for renal replacement therapy within 2 weeks from Baseline Subjects can have required short-term renal replacement therapy prior to Baseline, for example due to preceding acute kidney injury.

6. Infections:

   1. Untreated latent or active tuberculosis (TB);
   2. Chronic infections requiring treatment;
   3. A subject known to be infected with Human Immunodeficiency Virus (HIV), Hepatitis B;
   4. Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within 4 weeks prior of Baseline visit;
   5. Any treated infections within 2 weeks of Baseline visit;
   6. History of infected joint prosthesis with prosthesis still in situ;

7. Blood dyscrasias, including:

   1. Hemoglobin <8.5 g/dL or Hematocrit <22%;
   2. White Blood Cell count <2.6 x 109/L;
   3. Neutrophil count <1.2 x 109/L;
   4. Platelet count <100 x 109/L;
   5. Lymphocyte count <0.5 x 109/L.
8. Estimated glomerular filtration rate [GFR] <40 mL/min/1.73 m2 calculated using the modified Schwartz equation5 (see Appendix 4);
9. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal;
10. Vaccinated or exposed to a live or attenuated vaccine within the 4 weeks prior to Baseline visit;
11. History or current symptoms suggestive of lymphoproliferative disorders (e.g., Epstein Barr Virus [EBV] related lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorders, or multiple myeloma);
12. Current malignancy or history of any malignancy with the exception of adequate treated or excised basal cell or squamous cell or cervical cancer in situ;
13. Recent (within 4 weeks prior to Baseline visit) significant trauma or major surgery;
14. Herbal supplements with pharmaceutical properties must be discontinued at least 1week prior to Baseline visit, unless there are sufficient data available regarding the duration of an herbal medication's pharmacokinetic and pharmacodynamic effects to allow a shorter or longer washout to be specified (e.g., 5 half-lives).
15. Hydroxychloroquine exceeding 5mg/kg/day or started within 1 week prior to Baseline visit;
16. Oral or intravenous cyclophosphamide must be discontinued 12 weeks prior to Baseline visit
17. Rituximab or other selective B lymphocyte depleting agents: Must be discontinued for 6 months prior to Baseline visit or CD19/20+ counts must be normal by FACS analysis;
18. Use of prohibited prescription medication as listed in Appendix 3 within the specified time frame prior to Baseline visit
19. Participation in other studies involving investigational drug(s) within 4 weeks or 5 half-lives (whichever is longer) prior to Baseline visit and/or during study participation; Exposure to investigational biologics should be discussed with the Sponsor.
20. Pregnant female subjects; breastfeeding female subjects; male subjects with partners currently pregnant; male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use two highly effective methods of contraception or are abstinent (see Section 4.4.) for the duration of the study;
21. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: MMFBSA; MMF dosed as per body-surface area	Drug: Mycophenolate Mofetil; MMF dosed 600mg/m2 body surface area per dose about every 12 hours; Other Names: MMF dosed per body surface area; Drug: Mycophenolate Mofetil; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA >=60-70 mg*h/L; Other Names: MMF dosed phrmacokinetically
Experimental: MMFPK; MMF dosed as per pharmacokinetically-guided precision-dosing	Drug: Mycophenolate Mofetil; MMF dosed 600mg/m2 body surface area per dose about every 12 hours; Other Names: MMF dosed per body surface area; Drug: Mycophenolate Mofetil; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC 0-12h) of MPA >=60-70 mg*h/L; Other Names: MMF dosed phrmacokinetically

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare the efficacy of MMFPK therapy to the efficacy of MMFBSA therapy	the percentage of subjects achieving at least partial remission of LN (PRR) as per the adapted ACR/EULAR Criteria at Week 26	26 week

Collaborators and Investigators

• Sponsor: Children's Hospital Medical Center, Cincinnati
• Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Genentech, Inc.
• Investigators: Principal Investigator: Hermine I Brunner, MD, Children's Hospital Medical Center, Cincinnati

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2024
• Primary Completion (Estimated): July 1, 2025
• Study Completion (Estimated): March 1, 2026

Study Registration Dates

• First Submitted: September 9, 2022
• First Submitted That Met QC Criteria: September 9, 2022
• First Posted (Actual): September 13, 2022

Study Record Updates

• Last Update Posted (Estimated): January 11, 2024
• Last Update Submitted That Met QC Criteria: January 10, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Kidney Diseases; Urologic Diseases; Connective Tissue Diseases; Glomerulonephritis; Lupus Erythematosus, Systemic; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Nephritis; Lupus Nephritis; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antineoplastic Agents; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antitubercular Agents; Antibiotics, Antitubercular; Mycophenolic Acid
• Other Study ID Numbers: ML42264; 1R01AR079124-01A1 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

The Sponsor fulfills its commitment to publicly disclose clinical trial results through posting the results of studies on ClinicalTrials.gov, or EudraCT, and/or www.cincinnatichildrens.com, and other public registries in accordance with applicable local laws/regulations.

In all cases, study results are reported by the Sponsor regardless of the outcome of the study. Every effort will be made to report the basic results within 1 year of the end of the trial. Results will be posted at www.clinicaltrials.gov/.

For all publications relating to the study, the institution and investigators will comply with recognized ethical standards concerning publications and authorship, including Section II - "Ethical Considerations in the Conduct and Reporting of Research" of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship.

A Publication Committee will be established to oversee publication of the results.

• IPD Sharing Time Frame: within one year for
• IPD Sharing Access Criteria: results are available to the public

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes